Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SLAMF7

SLAMF7

Brief Information

Name:SLAM family member 7
Target Synonym:CS1,UNQ576/PRO1138,SLAMF7,Novel Ly9,SLAM Family Member 7,Membrane Protein FOAP-12,CD2 Subset 1,Protein 19A,CRACC,CD2-Like Receptor Activating Cytotoxic Cells,CD2-Like Receptor-Activating Cytotoxic Cells,19A24 Protein,CD319,19A,CD319 Antigen,Novel LY9 (Lymphocyte Antigen 9) Like Protein
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:4
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

SL7-HP2H3-Cell-based assay
 SLAMF7 FACS

1e6 of the anti-SLAMF7 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HP2H3) and negative control protein respectively, PE signals was used to evaluate the binding activity (QC tested).

SL7-HF2H7-Cell-based assay
 SLAMF7 FACS

2e5 of Anti-SLAMF7 CAR-293 cells were stained with 100 μL of 10 μg/mL of FITC-Labeled Human SLAMF7, His Tag (Cat. No. SL7-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested)

SL7-H5256-ELISA
 SLAMF7 ELISA

Immobilized Human SLAMF7, Fc Tag (Cat. No. SL7-H5256) at 1 μg/mL (100 μL/well) can bind Anti-SLAMF7/CS1 Antibody, Human IgG1 with a linear range of 0.2-2 ng/mL (QC tested).

SL7-R52H7-MALS-HPLC
SLAMF7 MALS images

The purity of Rhesus macaque SLAMF7, His Tag (Cat. No. SL7-R52H7) is more than 90% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

Synonym Name

SLAMF7,CD319,CS1,CRACC,19A,FOAP-12

Background

SLAM family member 7 (SLAMF7) is also known as CD2-like receptor-activating cytotoxic cells (CRACC), Membrane protein FOAP-12, CD antigen CD319, Novel Ly9, Protein 19A, which is a single-pass type I membrane protein and a member of the CD2 family of cell surface receptors. SLAMF7 is expressed in spleen, lymph node, peripheral blood leukocytes, bone marrow, small intestine, stomach, appendix, lung and trachea. Isoform 1 of SLAMF7 mediates NK cell activation through a SH2D1A-independent extracellular signal-regulated ERK-mediated pathway. May play a role in lymphocyte adhesion. Isoform 3 of SLAMF7 does not mediate any NK cell activation.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Elotuzumab PDL-063; HuLuc-63; BMS-901608 Approved Abbvie Inc, Bristol-Myers Squibb Company Empliciti United States Multiple Myeloma Bristol-Myers Squibb Company 2015-11-30 Hematologic Neoplasms; Hematopoietic stem cell transplantation (HSCT); Polycythemia Vera; Smoldering Multiple Myeloma; Leukemia, Plasma Cell; Multiple Myeloma; Primary Myelofibrosis; Lymphoma; Thrombocythemia, Essential Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
CS1 Targeted CAR T-cells (Yake Biotechnology) Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma Details
CD319 chimeric antigen T cell therapy (Wuhan Bio Raid Biotechnology) Clinical Wuhan Bio-Raid Biotechnology, Tongji Hospital Hematologic Neoplasms Details
SLAMF7 CAR-T cell therapy (Wuerzburg University Hospital) Phase 2 Clinical University Hospital Würzburg Multiple Myeloma Details
WS-CART-CS1 WS-CART-CS1 Phase 1 Clinical Washington University School Of Medicine, Paula C. & Rodger O. Riney Blood Cancer Research Multiple Myeloma Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message